American Journal of Tropical Medicine and Hygiene 2007-03-01

Tafenoquine for the treatment of recurrent Plasmodium vivax malaria.

Scott Kitchener, Peter Nasveld, Michael D Edstein

Index: Am. J. Trop. Med. Hyg. 76(3) , 494-6, (2007)

Full Text: HTML

Abstract

Tafenoquine was used to treat Plasmodium vivax malaria cases who had previously failed treatment with chloroquine and primaquine. Chloroquine was followed by a loading dose of tafenoquine (200 mg base/day for 3 days) and 200 mg a week was given for 8 weeks. One of 27 treated patients relapsed after 6 months of observation. A standard course of chloroquine administered with 8 weeks of tafenoquine may be more effective than chloroquine with primaquine (22.5 mg/day for 14 days) in preventing additional P. vivax relapses. Larger studies are required to optimize the combination, but our findings suggest that an extended use of tafenoquine may be required to prevent relapses of primaquine-tolerant strains of P. vivax malaria.

Related Compounds

Structure Name/CAS No. Articles
Tafenoquine (Succinate) Structure Tafenoquine (Succinate)
CAS:106635-81-8